Entries by SM

$AGN unusual approach to protect IP

We discuss Allergan’s (AGN) creative legal approach to protecting its IP for its RESTASIS drug by transferring all its patents to the Saint Regis Mohawk Tribe. Read the full discussion on our SeekingAlpha Marketplace page.

$NBRV further upside

Our daily analysis of a stock with a major event/upside: Nabriva (NBRV) stock doubled on 200x normal volume (Vol / Avg. 17.49M/74,701.00) on the back of positive results from one of two pivotal phase trials evaluating intravenous to oral lefamulin in patients with community-acquired bacterial pneumonia (CABP). Read full post in our daily pharma scoop […]

$NEOS saw a sell-off on Friday?

Neos Therapeutics (NEOS) saw a sell-off on Friday despite getting approval for its Adzenys ER treatment for ADHD that same day. Read our take on the news, in our Daily Pharma Scoop at SeekingAlpha Marketplace.

Why were we neutral on $ARRY?

Array BioPharma (ARRY) has a public offering of 20,930,232 shares of common stock at $10.75 per share. Stock is currently at $10.82. ... overall we were neutral.  Read why, in our Daily Pharma Scoop at SeekingAlpha Marketplace.

$RDUS insider purchases

Radius Health, Inc. (RDUS) insider purchases: 10% +$5,017,975 Pres, CEO +$199,608 CFO +$98,503 Check out all pharma insider purchases in our SeekingAlpha Marketplace Daily Pharma Scoop.  

$FGEN insider sales

Insider sales at Fibrogen Inc. Chief Medical Officer -$145,401 Dir -$1,298,000 CEO -$1,996,274 Check out all pharma insider sales in our SeekingAlpha Marketplace Daily Pharma Scoop.

$NLNK target raised nearly 300%

Jefferies Group Upgrades NewLink Genetics Corporation (NLNK) Hold -> Buy raising target $7.00 -> $26.00. Robert W. Baird also Upgrades NLNK Neutral -> Outperform raising target $8.00 -> $22.00. Cantor Fitzgerald Reiterates Overweight with target of $26.00. Check out more ratings and analysis on our SeekingAlpha Marketplace Daily Pharma Scoop.

Morgan Stanley Downgrades $MNK

Morgan Stanley Downgrades Mallinckrodt PLC (MNK) from Overweight -> Equal Weight reducing target $65.00 -> $40.00, while Piper Jaffray, Stifel Nicolaus, Mizuho, Cantor Fitzgerald reiterate BUY with targets ranging from $52 to $85. Get in-depth analysis in our Daily Pharma Scoop at SeekingAlpha Marketplace.